中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (9): 772-778.doi: 10.19401/j.cnki.1007-3639.2022.09.003
收稿日期:
2022-02-15
修回日期:
2022-06-21
出版日期:
2022-09-30
发布日期:
2022-10-24
通信作者:
徐近,虞先濬
作者简介:
高鹤丽(ORCID: 0000-0001-6094-5776),博士,主治医师。GAO Heli(), XU Jin(), YU Xianjun()
Received:
2022-02-15
Revised:
2022-06-21
Published:
2022-09-30
Online:
2022-10-24
Contact:
XU Jin, YU Xianjun
摘要:
胰腺神经内分泌肿瘤(pancreatic neuroendocrine neoplasm,PanNEN)发病率低且异质性强,有关PanNEN分子机制的研究逐渐增多,同时PanNEN临床诊断、治疗和预后预测也有新的进展。指南除常规推荐手术、介入治疗等局部治疗,以及生长抑素类似物、靶向治疗等系统治疗外,还存在一些手术问题和药物应用的争议,这些问题和争议也体现了PanNEN诊治过程中的个体化原则和全程管理。本文对2021年PanNEN基础和临床方面的研究进展进行综述。
中图分类号:
高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022, 32(9): 772-778.
GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021[J]. China Oncology, 2022, 32(9): 772-778.
[1] |
ALI H, PAMARTHY R, VALLABHANENI M, et al. Pancreatic cancer incidence trends in the United States from 2000-2017: analysis of Surveillance, Epidemiology and End Results (SEER) database[J]. F1000Res, 2021, 10: 529.
doi: 10.12688/f1000research.54390.1 pmid: 34527218 |
[2] | 中国临床肿瘤学会指南工作委员会. 神经内分泌肿瘤诊疗指南(2021)[M]. 北京: 人民卫生出版社, 2021. |
Guideline Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of neuroendocrine tumors (2021)[M]. Beijing: People’s Medical Publishing House, 2021. | |
[3] |
MANDAIR D, KHAN M S, LOPES A, et al. Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors[J]. J Clin Endocrinol Metab, 2020, 106(3): 872-882.
doi: 10.1210/clinem/dgaa822 |
[4] |
OVERSOE S K, SORENSEN B S, TABAKSBLAT E M, et al. Cell-free DNA and clinical characteristics in patients with small intestinal or pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(1): 43-50.
doi: 10.1159/000514457 |
[5] |
MALCZEWSKA A, WITKOWSKA M, WÓJCIK-GIERTUGA M, et al. Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience[J]. Neuroendocrinology, 2021, 111(4): 304-319.
doi: 10.1159/000508106 |
[6] |
MODLIN I M, KIDD M, FRILLING A, et al. Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost-effective and predicts neuroendocrine tumor recurrence with 94% accuracy[J]. Ann Surg, 2021, 274(3): 481-490.
doi: 10.1097/SLA.0000000000005026 |
[7] |
VAN TREIJEN M J C, VAN DER ZEE D, HEERES B C, et al. Blood molecular genomic analysis predicts the disease course of gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest®[J]. Neuroendocrinology, 2021, 111(6): 586-598.
doi: 10.1159/000509091 |
[8] | LLOYD R V, OSAMURA R Y, KLOPPEL G, et al. WHO classification of tumours of endocrine organs[M]. 5th ed. Lyon: IARC WHO Classification of Tumours, 2019, 10. |
[9] | National Comprehensive Cancer Network. Clinical practice guidelines in oncology: neuroendocrine and adrenal tumors (version 2. 2021)[EB/OL]. [2022-07-25]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448. |
[10] |
UEMURA J, OKANO K, OSHIMA M, et al. Immunohistochemically detected expression of ATRX, TSC2, and PTEN predicts clinical outcomes in patients with grade 1 and 2 pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6): e949-e956.
doi: 10.1097/SLA.0000000000003624 |
[11] |
SCARPA A, CHANG D K, NONES K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543(7643): 65-71.
doi: 10.1038/nature21063 |
[12] |
JIAO Y C, SHI C J, EDIL B H, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331(6021): 1199-1203.
doi: 10.1126/science.1200609 pmid: 21252315 |
[13] |
DI DOMENICO A, PIPINIKAS C P, MAIRE R S, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression[J]. Commun Biol, 2020, 3(1): 740.
doi: 10.1038/s42003-020-01479-y pmid: 33288854 |
[14] |
YOUNG K, LAWLOR R T, RAGULAN C, et al. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours[J]. Gut, 2021, 70(10): 1904-1913.
doi: 10.1136/gutjnl-2020-321016 pmid: 32883872 |
[15] |
VERDE F, GALATOLA R, ROMEO V, et al. Pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1: diagnostic value of different MRI sequences[J]. Neuroendocrinology, 2021, 111(7): 696-704.
doi: 10.1159/000509647 |
[16] |
YOO J, KIM S H, JEON S K, et al. Added value of[68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort[J]. Eur Radiol, 2021, 31(10): 7734-7745.
doi: 10.1007/s00330-021-07859-0 |
[17] |
PAIELLA S, LANDONI L, TEBALDI S, et al. Dual-tracer(68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases[J]. Neuroendocrinology, 2022, 112(2): 143-152.
doi: 10.1159/000514809 |
[18] |
VEENSTRA E B, DE GROOT D J A, BROUWERS A H, et al. Comparison of 18F-DOPA versus 68Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms[J]. Clin Nucl Med, 2021, 46(3): 195-200.
doi: 10.1097/RLU.0000000000003447 |
[19] |
HSU D, LE S, CHANG A, et al. Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?[J]. J Clin Oncol, 2021, 39(15_suppl): 4108.
doi: 10.1200/JCO.2021.39.15_suppl.4108 |
[20] |
ALTIMARI M, ABAD J, CHAWLA A. The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors[J]. HPB (Oxford), 2021, 23(10): 1533-1540.
doi: 10.1016/j.hpb.2021.03.005 |
[21] |
SAHARA K, TSILIMIGRAS D I, MORO A, et al. Long-term outcomes after spleen-preserving distal pancreatectomy for pancreatic neuroendocrine tumors: results from the US neuroendocrine study group[J]. Neuroendocrinology, 2021, 111(1/2): 129-138.
doi: 10.1159/000506399 |
[22] |
ASANO D, KUDO A, AKAHOSHI K, et al. Curative surgery and Ki-67 value rather than tumor differentiation predict the survival of patients with high-grade neuroendocrine neoplasms[J]. Ann Surg, 2020, 276(2): e108-e113.
doi: 10.1097/SLA.0000000000004495 |
[23] | 张中国抗癌协会胰腺癌专业委员会. 中国胰腺癌综合诊治指南(2020版)[J]. 中华外科杂志, 2021, 59(2): 81-100. |
Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2020 version)[J]. Chin J Surg, 2021, 59(2): 81-100. | |
[24] | TITAN A L, NORTON J A, FISHER A T, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11): e2024318. |
[25] |
PARGHANE R V, BHANDARE M, CHAUDHARI V, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors[J]. J Nucl Med, 2021, 62(11): 1558-1563.
doi: 10.2967/jnumed.120.258772 |
[26] |
GAO H L, LIU L, WANG W Q, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor[J]. Cancer Lett, 2018, 412: 188-193.
doi: S0304-3835(17)30673-0 pmid: 29107104 |
[27] |
WANG W Q, ZHANG W H, GAO H L, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4): 395-405.
doi: 10.1007/s00535-021-01777-0 |
[28] |
HEIDSMA C M, VAN ROESSEL S, VAN DIEREN S, et al. International validation of a nomogram to predict recurrence after resection of grade 1 and 2 nonfunctioning pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(6): 571-579.
doi: 10.1159/000518757 |
[29] |
PULVIRENTI A, JAVED A A, LANDONI L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6): 1051-1057.
doi: 10.1097/SLA.0000000000003579 |
[30] |
KULKARNI R, KABIR I, HODSON J, et al. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: a systematic review and meta-analysis[J]. Ann Hepatobiliary Pancreat Surg, 2022, 26(1): 31-39.
doi: 10.14701/ahbps.21-101 |
[31] |
TSILIMIGRAS D I, HYER J M, PAREDES A Z, et al. Resection of primary gastrointestinal neuroendocrine tumor among patients with non-resected metastases is associated with improved survival: a SEER-medicare analysis[J]. J Gastrointest Surg, 2021, 25(9): 2368-2376.
doi: 10.1007/s11605-020-04898-8 pmid: 33403563 |
[32] |
KAEMMERER D, TWRZNIK M, KULKARNI H R, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms[J]. Ann Surg, 2021, 274(1): e45-e53.
doi: 10.1097/SLA.0000000000003237 pmid: 33030849 |
[33] |
MEROLA E, FALCONI M, RINKE A, et al. Radical intended surgery for highly selected stage Ⅳ neuroendocrine neoplasms G3[J]. Am J Surg, 2020, 220(2): 284-289.
doi: 10.1016/j.amjsurg.2020.03.009 |
[34] |
JANSON E T, KNIGGE U, DAM G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J]. Acta Oncol, 2021, 60(7): 931-941.
doi: 10.1080/0284186X.2021.1921262 |
[35] |
AL-TOUBAH T, MORSE B, PELLE E, et al. Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide[J]. Oncologist, 2021, 26(2): 115-119.
doi: 10.1002/onco.13611 |
[36] | LACOMBE C, PERRIER M, HENTIC O, et al. FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors[J]. Ann Oncol, 2021, 32: S621. |
[37] |
DE RYCKE O, WALTER T, PERRIER M, et al. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors[J]. Endocr Relat Cancer, 2021, 28(7): 457-466.
doi: 10.1530/ERC-21-0034 |
[38] | MCGARRAH P W, HOBDAY T J, STARR J S, et al. Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)[J]. J Clin Oncol, 2020, 38(4_suppl): 617. |
[39] | LEPAGE C, PHELIP J M, LIÈVRE A, et al. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S774. |
[40] | DEHEZ M, BRENDEL K, SARR C, et al. CLARINET FORTE: characterization of pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with lanreotide autogel (LAN) 120 mg every 14 days (q14d)[C]. 18th Annual ENETS Conference, 2021. |
[41] |
PAVEL M, ĆWIKŁA J B, LOMBARD-BOHAS C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results[J]. Eur J Cancer, 2021, 157: 403-414.
doi: 10.1016/j.ejca.2021.06.056 pmid: 34597974 |
[42] |
XU J M, SHEN L, BAI C M, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11): 1489-1499.
doi: 10.1016/S1470-2045(20)30493-9 pmid: 32966810 |
[43] |
CAPDEVILA J, FAZIO N, LOPEZ C, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase Ⅱ TALENT trial (GETNE1509)[J]. J Clin Oncol, 2021, 39(20): 2304-2312.
doi: 10.1200/JCO.20.03368 |
[44] |
CLEMENT D, NAVALKISSOOR S, SRIRAJASKANTHAN R, et al. Efficacy and safety of 177Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry[J]. J Clin Oncol, 2021, 39(15_suppl): 4116.
doi: 10.1200/JCO.2021.39.15_suppl.4116 |
[45] |
COFFMAN K L, BODEI L S, LE T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE[J]. J Clin Oncol, 2021, 39(3_suppl): 368.
doi: 10.1200/JCO.2021.39.3_suppl.368 |
[46] |
RINKE A, AUERNHAMMER C J, BODEI L S, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?[J]. Gut, 2021, 70(9): 1768-1781.
doi: 10.1136/gutjnl-2020-321300 pmid: 33692095 |
[47] |
GRANDE E, RODRIGUEZ-ANTONA C, LÓPEZ C, et al. Sunitinib and evofosfamide (TH-302) in systemic treatment-naïve patients with grade 1/2 metastatic pancreatic neuroendocrine tumors: the GETNE-1408 trial[J]. Oncologist, 2021, 26(11): 941-949.
doi: 10.1002/onco.13885 |
[48] | CORTI F, AMOROSO V, CAMPANA D, et al. Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): the phase Ⅱ LOLA trial[J]. J Clin Oncol, 2021, 39(15_suppl): TPS4167. |
[49] |
STROSBERG J, MIZUNO N, DOI T, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study[J]. Clin Cancer Res, 2020, 26(9): 2124-2130.
doi: 10.1158/1078-0432.CCR-19-3014 |
[50] |
HERNANDO J, MANZANO J L, TEULE A, et al. Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: results from the phase Ⅱ DUNE trial (GETNE 1601)[J]. Ann Oncol, 2021, 32: S909-S910.
doi: 10.1016/j.annonc.2021.08.181 |
[51] | MANDRIANI B, PELLE E, MANNAVOLA F, et al. Development of CAR T-cells for future treatment of NETs[J]. Ann Oncol, 2021, 32: S911. |
[52] | BUTT B P, STOKMO H L, LADEKARL M, et al. Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas[J]. Ann Oncol, 2021, 32: S915. |
[53] |
RIESCO-MARTINEZ M C, CAPDEVILA J, ALONSO V, et al. Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913)[J]. Ann Oncol, 2021, 32: S908-S909.
doi: 10.1016/j.annonc.2021.08.180 |
[54] | SHEN L, YU X J, LU M, et al. Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: results from a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2021, 39(15_suppl): e16199. |
[1] | 王先泽, 吴文铭. 胰腺神经内分泌肿瘤外科治疗理念的四种转变[J]. 中国癌症杂志, 2022, 32(9): 765-771. |
[2] | 张日虹, 郭宇, 梁贇, 陈洛海, 陈洁, 王玮. 辅助化疗对胃神经内分泌癌患者预后的意义[J]. 中国癌症杂志, 2022, 32(9): 807-817. |
[3] | 肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679. |
[4] | 张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022, 32(8): 688-697. |
[5] | 周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展:联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704. |
[6] | 陈安莉, 沈浩元, 阳仕雄, 邓春燕, 胡超华, 刘汉忠, 王舒, 钱芳. 血浆长链非编码RNA H19对乳腺癌新辅助治疗效果的预测价值[J]. 中国癌症杂志, 2022, 32(8): 727-735. |
[7] | 中国抗癌协会妇科肿瘤专业委员会, 中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 妇科恶性肿瘤多学科诊疗中国专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(8): 747-756. |
[8] | 蔡钢, 王舒蓓, 陈佳艺. 放射治疗在胃癌全程管理中的现状与挑战[J]. 中国癌症杂志, 2022, 32(7): 581-587. |
[9] | 曹孟轩, 胡灿, 张延强, 黄灵, 杜义安, 于鹏程, 章若岚, 徐志远, 程向东. 胃癌根治术后早期复发转移的危险因素分析[J]. 中国癌症杂志, 2022, 32(7): 588-595. |
[10] | 钱瑶, 刘锋. 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649. |
[11] | 刘彦权, 胡晓梅, 殷悦, 林霖, 沈建箴, 陈玉婷, 唐焕文. 器官移植术后淋巴组织增生性疾病的临床回顾性研究[J]. 中国癌症杂志, 2022, 32(7): 650-656. |
[12] | 苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486. |
[13] | 虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗:现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498. |
[14] | 胡夕春, 胡志皇, 王碧芸, 王佳蕾, 陶荣, 张剑, 郭伟剑, 陈洁, 罗志国, 李婷, 黄明主, 邱立新, 桑友洲. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511. |
[15] | 李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测:现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
地址:上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室
邮编:200032 电话:021-64188274 E-mail:zgazzz@china-oncology.com
访问总数:; 今日访问总数:; 当前在线人数:
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn